Navigation Links
Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
Date:9/23/2008

SOUTH SAN FRANCISCO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that it has initiated a study, in collaboration with the Dana-Farber Cancer Institute (DFCI), to evaluate Monogram's HERmark(TM) Breast Cancer Assay in metastatic breast cancer.

In the study, Monogram's proprietary HERmark assay will be used to analyze approximately 600 tissue samples from patients with breast cancer, approximately half of whom were eligible for treatment with Herceptin(R) on the basis of prior HER2 IHC and/or FISH testing. HERmark measurements of HER2 total protein and HER2 homodimer levels will be compared with the results of IHC and/or FISH testing as well as response to treatment with Herceptin.

"Results from prior studies in metastatic breast cancer have suggested that HERmark can identify subsets of patients with different responses to Herceptin even though they had all been previously assessed as 'HER2-positive' by IHC and/or FISH, tested centrally," said Michael Bates, M.D., Monogram's Vice President of Clinical Research. "The aim of this study is to test the hypothesis that HERmark selects patients for Herceptin treatment in the metastatic setting better than other currently available assays, as well as to test cutoff values that have been previously defined for HERmark. In addition, we will also measure HER3 expression levels in these tumors and see if they correlate with clinical outcomes in this cohort. The study will also provide enough tissue to facilitate testing of assays that are in advanced development at Monogram, including assays for HER1 expression, p95 expression, as well as heterodimers of HER2, such as HER2:HER3 and HER1:HER2."

"The VeraTag technology repres
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
3. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
4. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
5. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
6. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
7. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... New York, NY (PRWEB) October 30, 2014 ... investment plan for its ICH Stability Testing and Package ... companies, this investment centers on a dramatic increase in ... larger volume of stability, storage and aging samples to ... first stage of this major capital expenditure has already ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Inc. (NYSE: CRY ), an implantable biological medical ... it has filed an IDE with the United States ... the purpose of obtaining Pre-Market Approval (PMA) to distribute PerClot ... following traumatic injuries. PerClot is a unique, ...
... EMERYVILLE, Calif., April 4, 2011 Newly proposed ... patient care under healthcare reform closely mirror quality ... the American healthcare system, a MedeAnalytics analysis has ... The quality measure analysis is included ...
... April 4, 2011 Techne Corporation (NASDAQ: ... April 1, 2011, its R&D Systems subsidiary has ... leading developer and manufacturer of innovative ubiquitin-related research ... that facilitate and accelerate basic research and drug ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4ACO Proposed Rule: Nine out of Ten Quality Measures Mirror Other Quality Reporting Programs 2Techne Corporation Announces Acquisition 2Techne Corporation Announces Acquisition 3Techne Corporation Announces Acquisition 4
(Date:10/28/2014)... Health (NIH) announced awards to expand the Office ... Center for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare ... network, physician scientists at 22 consortia will work ... research and investigate new treatments for patients with ... $29 million in fiscal 2014 funding from NIH. ...
(Date:10/28/2014)... in a novel environment are linked to individual ... experimental study completed at the University of Eastern ... Institute. The study used novel, long-term observations of ... to analyse if behaviours predict the vulnerability to ... enriched hatchery rearing environments. Based on the ...
(Date:10/28/2014)... associated with a lower risk of developing ovarian cancer, ... Anglia (UEA). , Research published today reveals that ... subclasses of dietary flavonoids) significantly decrease their risk of ... death among women. , The research team studied ... and 55 for more than three decades. , ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Fish 'personality' linked to vulnerability to angling 2Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
... for a University of Alberta paleontology researcher, who after months of ... as a new species of pterosaur, a flying reptile that lived ... stumped when the small piece of jaw bone was first pulled ... A,s paleontology department. "It could have been from a dinosaur, ...
... 4, 2011) − Scientists at the University of Kentucky have ... break up blood clots, speeds up the progress of prion ... plasminogen a promising new target for the development of drugs ... senior author Chongsuk Ryou, a researcher at the UK Sanders-Brown ...
... Lithuania, Jan. 10, 2011 Neurotechnology , ... announced the release of MegaMatcher 4.0 , ... fingerprint, iris, facial and palmprint biometrics in a ... MegaMatcher 4.0, Neurotechnology has incorporated palmprint technology along ...
Cached Biology News:Research identifies drug target for prion diseases, 'mad cow' 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 3
... deuterium atoms at the 3, 3', 4, ... use as an internal standard for the ... spectrometry. PGE1 is the theoretical cyclooxygenase metabolite ... virtually undetectable in the plasma of normal ...
Assay Diluent Trial Pack, 4 x 100 mL...
... Turn routine agarose gel electrophoresis into ... 96 system. This bufferless, pre-cast system is ... preparations, restriction digests, and more. Fully automated, ... the E-Gel 96 system makes your high-throughput ...
... The CopyControl™ PCR Cloning Kits are designed ... to ensure that all PCR products, regardless of ... cloned. All PCR products including those that are ... or that may be unstable or code for ...
Biology Products: